This lawsuit trails on the heels of an earlier judgment, where a New Jersey state appeals court sided with McCarter & English, to the tune of $860,000, for Moerae’s outstanding legal fees.
However, the biotech firm asserts that its inability to settle the fees led McCarter & English down a murky path.
Allegedly, the law firm took undue steps by involving the Delaware Department of State and the U.S. Patent and Trademark Office, asserting a false security interest in Moerae’s patent vault.
In the corridors of power and the high-stakes world of intellectual property, Moerae claims such filings were not just false but calamitous.
The fallout? An uphill battle for Moerae to secure funding, push forward clinical trials for their flagship drug, MMI-0100, and a potential roadblock in getting the coveted nod from the U.S. Food and Drug Administration.
Layers of Allegations: Beyond Malpractice
Moerae’s discontent isn’t just limited to legal malpractice.
They’ve thrown the book at their former counsel, including accusations of breach of fiduciary duty, slander of title to property, and malice in meddling with potential economic opportunities.
